Choose Your Country or Region

Integrin

Isoform-selective Products

ILK

Signaling Pathway

Integrin Products

All (33)
Integrin Inhibitors (12)
Integrin Antibodies (12)
Integrin Antagonists (7)
Integrin Agonists (2)
New Integrin Products

Catalog No.	Product Name	Information	Product Use Citations
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	Adv Sci (Weinh), 2023, e2307206. Heliyon, 2023, 9(9):e20185 Heliyon, 2023, 9(9):e20185
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-707544) is a potent and selective inhibitor of the integrins α_νβ₃ and α_νβ₅ with IC50 of 4 and 79 nM, respectively.	NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741 Cancer Cell, 2023, 41(8):1480-1497.e9
S7540	SB273005	SB273005 is a potent integrin inhibitor with K_i of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	Cancer Lett, 2024, 582:216597 Nat Commun, 2023, 14(1):3251 Neuron, 2023, S0896-6273(23)00623-2
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119 Cell Stem Cell, 2023, 30(6):867-884.e11
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2024, 15(1):5986 Int Immunopharmacol, 2024, 141:112947 Bioact Mater, 2023, 22:75-90
S7844	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.	J Clin Invest, 2024, e175147 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7 iScience, 2023, 26(6):106839
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is a potent and selective αvβ3 integrin inhibitor.	Sci Adv, 2024, 10(43):eadp4726 bioRxiv, 2024, 2024.09.17.613509 Oxidative Medicine and Cellular Longevity, 2021, 10.1155/2021/9739977
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 Med Chem Res, 2022, 31(4):555-579
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. OSU-T315 induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. OSU-T315 exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
A2420	Anti-Integrin b1 / ITGB1 / CD29	Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.
A2873	Anti-ICAM3 / CD50	Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
E1558^New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615^New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
A2464	Bersanlimab (Anti-ICAM1 / CD54)	Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD.
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. RGD peptide (GRGDNP) induces apoptosis presumably through direct activation of caspase-3.
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
A2704	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100)	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD.
A2712	Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)	Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
A2988	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
A2990	Intetumumab (Anti-Integrin aV / ITGAV / CD51)	Intetumumab (Anti-Integrin aV / ITGAV / CD51) is a potent monoclonal antibody targeting αV-integrins. It can be used in research of uterine serous papillary carcinoma (USPC) treatment. MW :145.58 KD.
A2991	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3))	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD.
A2744	Abituzumab (Anti-Integrin aV / ITGAV / CD51)	Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD.
A2745	Anti-Integrin a11 / ITAG11	Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD.
A2761	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7)	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD.
E1385^New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
A2045	Vedolizumab (anti-α4β7-integrin)	Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
S7077	Cilengitide trifluoroacetate	Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.	Adv Sci (Weinh), 2023, e2307206. Heliyon, 2023, 9(9):e20185 Heliyon, 2023, 9(9):e20185
S6387	Cilengitide	Cilengitide (EMD 121974, EMD-12192, EMD-85189, NSC-707544) is a potent and selective inhibitor of the integrins α_νβ₃ and α_νβ₅ with IC50 of 4 and 79 nM, respectively.	NPJ Regen Med, 2024, 9(1):4 World J Gastroenterol, 2024, 30(7):728-741 Cancer Cell, 2023, 41(8):1480-1497.e9
S7540	SB273005	SB273005 is a potent integrin inhibitor with K_i of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.	Cancer Lett, 2024, 582:216597 Nat Commun, 2023, 14(1):3251 Neuron, 2023, S0896-6273(23)00623-2
S8008	RGD (Arg-Gly-Asp) Peptides	RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.	J Sport Health Sci, 2024, S2095-2546(24)00124-8 iScience, 2024, 27(3):109119 Cell Stem Cell, 2023, 30(6):867-884.e11
S7844	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.	J Clin Invest, 2024, e175147 Cell Commun Signal, 2023, 10.1186/s12964-022-01027-7 iScience, 2023, 26(6):106839
S7834	Cyclo(-RGDfK) TFA	Cyclo(-RGDfK) TFA is a potent and selective αvβ3 integrin inhibitor.	Sci Adv, 2024, 10(43):eadp4726 bioRxiv, 2024, 2024.09.17.613509 Oxidative Medicine and Cellular Longevity, 2021, 10.1155/2021/9739977
S2885	A-205804	A-205804 is a potent and selective inhibitor of E-selectin and ICAM-1 expression with IC50 of 20 nM and 25 nM respectively.	Cell Biol Toxicol, 2024, 40(1):90 Stem Cell Res Ther, 2022, 13(1):218 Am J Rhinol Allergy, 2022, 19458924221086061
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. OSU-T315 induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. OSU-T315 exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
S4513	RGD peptide (GRGDNP)	RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. RGD peptide (GRGDNP) induces apoptosis presumably through direct activation of caspase-3.
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
E1385^New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.
A2420	Anti-Integrin b1 / ITGB1 / CD29	Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD.
A2873	Anti-ICAM3 / CD50	Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.
A2464	Bersanlimab (Anti-ICAM1 / CD54)	Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD.
A2704	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100)	Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanized monoclonal antibody directed against the alpha v beta 6 (αvβ6) integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW : 144.88 kD.
A2712	Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)	Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
A2988	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1))	Vatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
A2990	Intetumumab (Anti-Integrin aV / ITGAV / CD51)	Intetumumab (Anti-Integrin aV / ITGAV / CD51) is a potent monoclonal antibody targeting αV-integrins. It can be used in research of uterine serous papillary carcinoma (USPC) treatment. MW :145.58 KD.
A2991	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3))	Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD.
A2744	Abituzumab (Anti-Integrin aV / ITGAV / CD51)	Abituzumab (Anti-Integrin aV / ITGAV / CD51) is a humanized monoclonal antibody directed against the human alpha v integrin subunit with potential antiangiogenic and antineoplastic activities.MW: 144.78 kD.
A2745	Anti-Integrin a11 / ITAG11	Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD.
A2761	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7)	Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD.
A2045	Vedolizumab (anti-α4β7-integrin)	Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
S8454	ATN-161	ATN-161 is a novel small peptide antagonist of integrin α5β1. It binds to several integrins, including α5β1 and αvβ3, that play a role in angiogenesis and tumor progression.	Nat Commun, 2024, 15(1):5986 Int Immunopharmacol, 2024, 141:112947 Bioact Mater, 2023, 22:75-90
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World J Gastroenterol, 2023, 29(20):3103-3118 Med Chem Res, 2022, 31(4):555-579
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Food Funct, 2020, 11(1):139-152
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 39:101813 Front Cell Infect Microbiol, 2021, 11:783085
E1558^New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E4615^New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
S8306	Leukadherin-1	Leukadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1(an agonist for the complement receptor 3 (CD11b/CD18)).	International Immunopharmacology, 2023, Volume 118 Int Immunopharmacol, 2023, 118:110024 Front Immunol, 2022, 13:919444
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Signal Transduct Target Ther, 2024, 9(1):109 Signal Transduct Target Ther, 2024, 9(1):109
E1558^New	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
E4615^New	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.
E1385^New	Bexotegrast	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Choose Selective Integrin Inhibitors